GH – Guardant Health, Inc.
Guardant Health, Inc.GH
$41.36Name : Guardant Health, Inc.
Sector : Healthcare
Industry: Diagnostics & Research
Mark. Cap: $5,124,007,936.00
EPSttm : -3.39
Guardant Health, Inc.
$41.36
0.72%$0.3Float Short %
6.56
Margin Of Safety %
Put/Call OI Ratio
1.13
EPS Next Q Diff
0.31
EPS Last/This Y
1.5
EPS This/Next Y
0.3
Price
41.36
Target Price
58.86
Analyst Recom
1.52
Performance Q
-5.14
Relative Volume
0.62
Beta
1.41
Ticker: GH
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-04-14 | GH | 45.18 | 1.12 | 0.07 | 55454 |
| 2025-04-15 | GH | 44.84 | 1.12 | 14.17 | 55521 |
| 2025-04-16 | GH | 45.13 | 1.14 | 0.14 | 56126 |
| 2025-04-17 | GH | 44.93 | 1.14 | 0.06 | 56062 |
| 2025-04-18 | GH | 44.97 | 1.14 | 0.14 | 56062 |
| 2025-04-21 | GH | 42.59 | 1.03 | 1.14 | 34631 |
| 2025-04-22 | GH | 43.77 | 1.03 | 0.55 | 35013 |
| 2025-04-23 | GH | 45.62 | 1.03 | 0.14 | 35391 |
| 2025-04-24 | GH | 47.4 | 1.00 | 0.10 | 36111 |
| 2025-04-25 | GH | 48.3 | 0.99282742006132 | 0.056503198294243 | 36397 |
| 2025-04-28 | GH | 47.99 | 0.95327249842668 | 13.476331360947 | 37245 |
| 2025-04-29 | GH | 49.57 | 1.18 | 0.13 | 41944 |
| 2025-04-30 | GH | 47.16 | 1.17 | 1.74 | 42357 |
| 2025-05-01 | GH | 48.92 | 1.20 | 6.37 | 51774 |
| 2025-05-02 | GH | 46.9 | 1.05 | 1.35 | 50525 |
| 2025-05-05 | GH | 44.03 | 1.07 | 0.18 | 52473 |
| 2025-05-06 | GH | 41.92 | 1.06 | 1.83 | 52761 |
| 2025-05-07 | GH | 39.74 | 1.06 | 2.17 | 53030 |
| 2025-05-08 | GH | 41.66 | 1.10 | 0.62 | 55014 |
| 2025-05-09 | GH | 41.75 | 1.09 | 0.15 | 55185 |
| 2025-05-12 | GH | 41.64 | 1.08 | 1.93 | 55665 |
| 2025-05-13 | GH | 41.33 | 1.13 | 0.32 | 57916 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-04-14 | GH | 45.16 | -26.6 | -25.8 | -2.15 |
| 2025-04-15 | GH | 44.85 | -27.1 | -9.5 | -2.15 |
| 2025-04-16 | GH | 45.18 | -27.1 | -15.3 | -2.15 |
| 2025-04-17 | GH | 44.97 | -27.9 | -10.4 | -2.15 |
| 2025-04-18 | GH | 44.97 | -27.9 | -12.3 | -2.15 |
| 2025-04-21 | GH | 42.61 | -27.9 | 9.1 | -2.15 |
| 2025-04-22 | GH | 43.80 | -27.9 | -23.6 | -2.15 |
| 2025-04-23 | GH | 45.64 | -28.3 | -29.4 | -2.15 |
| 2025-04-24 | GH | 47.40 | -28.3 | -28.1 | -2.15 |
| 2025-04-25 | GH | 48.30 | -28.3 | -20.0 | -2.15 |
| 2025-04-28 | GH | 47.99 | -28.3 | -9.7 | -2.15 |
| 2025-04-29 | GH | 49.53 | -28.3 | -25.5 | -2.15 |
| 2025-04-30 | GH | 47.22 | -28.3 | 6.8 | -2.15 |
| 2025-05-01 | GH | 48.89 | -28.3 | -47.4 | -2.15 |
| 2025-05-02 | GH | 46.85 | -15.5 | -26.9 | -2.15 |
| 2025-05-05 | GH | 44.03 | -13.0 | 10.4 | -2.08 |
| 2025-05-06 | GH | 41.89 | -12.2 | 6.0 | -2.06 |
| 2025-05-07 | GH | 39.74 | -12.2 | 7.2 | -2.06 |
| 2025-05-08 | GH | 41.65 | -12.2 | -30.9 | -2.06 |
| 2025-05-09 | GH | 41.72 | -12.2 | -13.1 | -2.06 |
| 2025-05-12 | GH | 41.66 | -12.2 | -12.2 | -2.06 |
| 2025-05-13 | GH | 41.36 | -12.2 | -10.0 | -2.06 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-04-14 | GH | -0.39 | -5.10 | 7.08 |
| 2025-04-15 | GH | -0.39 | -5.10 | 7.08 |
| 2025-04-16 | GH | -0.39 | -5.10 | 7.08 |
| 2025-04-17 | GH | -0.39 | -5.10 | 7.08 |
| 2025-04-18 | GH | -0.39 | -5.10 | 7.08 |
| 2025-04-21 | GH | -0.39 | -5.09 | 7.08 |
| 2025-04-22 | GH | -0.39 | -5.09 | 7.08 |
| 2025-04-23 | GH | -0.39 | -5.09 | 7.08 |
| 2025-04-24 | GH | -0.39 | -5.09 | 7.08 |
| 2025-04-25 | GH | -0.39 | -5.09 | 7.08 |
| 2025-04-28 | GH | -0.39 | -7.27 | 6.51 |
| 2025-04-29 | GH | -0.39 | -7.27 | 6.51 |
| 2025-04-30 | GH | -0.39 | -7.27 | 6.51 |
| 2025-05-01 | GH | -0.39 | -7.27 | 6.51 |
| 2025-05-02 | GH | -0.39 | -7.27 | 6.51 |
| 2025-05-05 | GH | -0.39 | -6.34 | 6.48 |
| 2025-05-06 | GH | -2.23 | -6.34 | 6.48 |
| 2025-05-07 | GH | -2.22 | -6.34 | 6.48 |
| 2025-05-08 | GH | -2.22 | -6.34 | 6.48 |
| 2025-05-09 | GH | -2.26 | -6.34 | 6.48 |
| 2025-05-12 | GH | -2.26 | -3.17 | 6.56 |
| 2025-05-13 | GH | -2.26 | -3.17 | 6.56 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.82
Avg. EPS Est. Current Quarter
-0.54
Avg. EPS Est. Next Quarter
-0.51
Insider Transactions
-2.26
Institutional Transactions
-3.17
Beta
1.41
Average Sales Estimate Current Quarter
211
Average Sales Estimate Next Quarter
226
Fair Value
Quality Score
27
Growth Score
54
Sentiment Score
58
Actual DrawDown %
77.2
Max Drawdown 5-Year %
-91
Target Price
58.86
P/E
Forward P/E
PEG
P/S
6.62
P/B
P/Free Cash Flow
EPS
-3.38
Average EPS Est. Cur. Y
-2.06
EPS Next Y. (Est.)
-1.76
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-53.82
Relative Volume
0.62
Return on Equity vs Sector %
142.4
Return on Equity vs Industry %
155.4
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.08
EBIT Estimation
-10
Guardant Health, Inc.Sector: Healthcare
Industry: Diagnostics & Research
Employees: 1999
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI blood test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for adjuvant treatment and surveillance settings in early-stage cancer patients; and Smart Liquid Biopsy Platform. In addition, the company provides development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
stock quote shares GH – Guardant Health, Inc. Stock Price stock today
news today GH – Guardant Health, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch GH – Guardant Health, Inc. yahoo finance google finance
stock history GH – Guardant Health, Inc. invest stock market
stock prices GH premarket after hours
ticker GH fair value insiders trading